Physician profile
Michael Sacher
NPI 1831174473
$3,795.06
in general payments reported to CMS, 2019-2025
28 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $485 · 2021: $532 · 2022: $420 · 2023: $670 · 2024: $651 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $570.99 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $495.31 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $477.54 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Abbott Laboratories | $458.90 | 2023-2025 | Jot Dx, Aveir, Assurity |
| Amarin Pharma, INC. | $258.13 | 2019-2023 | |
| Novo Nordisk INC | $228.20 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.40 | 2020-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $183.14 | 2020-2024 | |
| Esperion Therapeutics, INC. | $141.78 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $89.88 | 2019-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $75.99 | 2024 | Verquvo |
| Pfizer INC. | $73.28 | 2019-2025 | |
| Medicomp INC | $63.61 | 2022-2024 | Telepatch Cardiac Monitor |
| Boston Scientific Corporation | $59.95 | 2023-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Sanofi-Aventis U.S. LLC | $54.30 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $35.40 | 2020-2023 | Livalo |
| Astellas Pharma US INC | $33.48 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.68 | 2025 | |
| Currax Pharmaceuticals LLC | $30.23 | 2025 | Contrave |
| Regeneron Healthcare Solutions, INC. | $29.61 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $29.25 | 2023 | Inpefa |
| Infobionic, INC | $25.93 | 2019 | |
| Impulse Dynamics (USA) INC. | $23.80 | 2021 | |
| Medtronic, INC. | $21.28 | 2025 | Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.87 | 2025 | Lifevest |
| Arbor Pharmaceuticals, INC. | $19.77 | 2019 | |
| Lilly USA, LLC | $18.83 | 2023 | Mounjaro |
| Gilead Sciences, INC. | $17.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.